Market Overview

Merck Says FDA Acknowledged Resubmission of NDA for Ezetimibe, Atorvastatin Tablets

Share:
Related MRK
Barron's Recap: What's Next?
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN and the TECOS Cardiovascular Safety Trial of JANUVIA Will Be Presented at the European Society of Cardiology Congress
An 80/20 Filter On How The DJIA Weathered The Week (Seeking Alpha)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine. The updated NDA was deemed complete for review after Merck submitted additional data in response to the FDA's Complete Response Letter issued last year. Merck expects the FDA's review to be completed in the first half of 2013.

Merck is continuing to move forward with planned filings for the ezetimibe and atorvastatin combination tablet in additional countries around the world.

Posted-In: News FDA

 

Related Articles (MRK)

Get Benzinga's Newsletters